Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
出版年份 2018 全文链接
标题
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
作者
关键词
Melanoma, CTLA4, Ipilimumab, Regulatory T cells, MDSC, Tumor antigens
出版物
Journal of Translational Medicine
Volume 16, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-07-04
DOI
10.1186/s12967-018-1563-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adjuvant Therapy for Melanoma
- (2017) Aya Agha et al. Current Oncology Reports
- CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes.
- (2017) A. Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
- (2014) Yago Pico de Coaña et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- (2014) L. Robert et al. CLINICAL CANCER RESEARCH
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- Increased frequencies of CD11b+CD33+CD14+HLA-DRlowmyeloid-derived suppressor cells are an early event in melanoma patients
- (2014) Berenice M. Rudolph et al. EXPERIMENTAL DERMATOLOGY
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients
- (2013) Kimberly R. Jordan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
- (2013) Y. P. de Coana et al. Cancer Immunology Research
- Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
- (2012) A. Gros et al. CLINICAL CANCER RESEARCH
- Phenotypic and functional characteristics of CD4+CD39+ FOXP3+ and CD4+CD39+FOXP3neg T-cell subsets in cancer patients
- (2012) Patrick J. Schuler et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
- (2012) Ahmad A. Tarhini et al. JOURNAL OF IMMUNOTHERAPY
- Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment of the Spleen
- (2012) Stefano Ugel et al. Cell Reports
- A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
- (2011) S. Solito et al. BLOOD
- Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
- (2011) Paola Filipazzi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets
- (2011) Patrick J. Schuler et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
- (2011) Jeffrey S. Weber et al. JOURNAL OF IMMUNOTHERAPY
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
- (2010) Isabel Poschke et al. CANCER RESEARCH
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity
- (2010) Je-In Youn et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression
- (2009) Magis Mandapathil et al. JOURNAL OF IMMUNOLOGICAL METHODS
- No Correlation Between Clinical Response to CTLA-4 Blockade and Presence of NY-ESO-1 Antibody in Patients With Metastatic Melanoma
- (2009) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
- (2008) C. Marcela Diaz-Montero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
- (2008) C. Menard et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now